Close menu




June 4th, 2026 | 07:45 CEST

Takeover Fever! BioNxt Solutions, Delivery Hero, and Commerzbank in the Spotlight: How Investors Can Benefit!

  • Biotechnology
  • Biotech
  • Banking
  • Investments
  • Takeover
  • Food
Photo credits: Pixabay

The entry of a strategic investor or the prospect of a takeover regularly leads to significant price surges and even massive revaluations. The momentum is enormous; the global market for mergers and acquisitions has reached new records. Especially during periods of technological upheaval, geopolitical realignment, and increasing competitive pressure, companies are increasingly turning to acquisitions to secure growth, resources, or market share. In this context, there are exciting and lucrative developments for investors at BioNxt Solutions, Delivery Hero, and Commerzbank. The investment case for BioNxt Solutions is particularly compelling. The Canadian company aims to bring an alternative to weight-loss injections to market. If successful, this could create a billion-dollar business and attract acquirers. How should investors position themselves?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: Bionxt Solutions Inc. | CA0909741062 | CSE:BNXT , OTCQB: BNXTF , DELIVERY HERO SE NA O.N. | DE000A2E4K43 , COMMERZBANK AG | DE000CBK1001

Table of contents:


    BioNxt Solutions: A Potential Alternative to Weight-Loss Injections Opens Up a Multi-Billion-Dollar Market

    With its proprietary platforms, the Canadian life sciences company focuses on next-generation drug delivery systems, diagnostic screening technologies, and the development of pharmaceutical active ingredients.

    Its portfolio includes sublingual thin films, transdermal patches, oral tablets, and a new platform for targeted chemotherapy. The patient is at the core of its approach. The company delivers patient-friendly, needle-free drug delivery technologies that aim to improve comfort, portability, and treatment adherence. This is a key differentiating factor.

    A central focus of its activities is oral dissolvable film (ODF) technologies, in which active ingredients are administered as fast-dissolving films through the oral mucosa. This allows for easier administration of medication while potentially improving bioavailability.

    The company recently announced a key milestone. The program for orally dissolving semaglutide films (ODF), in collaboration with the German drug development partner Gen-Plus, has entered the active pharmaceutical development phase.

    With this step, the Canadian company is expanding into the rapidly growing global market for GLP-1 therapies such as semaglutide. Until now, the company had primarily focused on neurological and autoimmune diseases. This development marks its transition toward a broader drug delivery platform company.

    According to the company, the first phase of the semaglutide development program is expected to last six to nine months. Semaglutide is a GLP-1 receptor agonist originally developed for the treatment of type 2 diabetes, but it is now best known for its strong weight-loss effects.

    The market for "weight-loss injections" is a multi-billion-dollar business and one of the fastest-growing segments in the pharmaceutical industry, with established players such as Novo Nordisk already well positioned. If oral administration proves successful, the Canadian company could become an attractive licensing or acquisition target. The company is currently valued at just under CAD 50 million at a share price of around CAD 0.40. This valuation does not reflect the enormous market potential.

    Delivery Hero: Uber is Ramping Up its Investment Significantly

    The company is one of the world's largest delivery platforms for food, groceries, and everyday products, operating in around 70 countries. Its business model is based on delivery fees, commissions from restaurants, and, increasingly, quick-commerce offerings for groceries and daily necessities.

    The global delivery market is undergoing a wave of consolidation. Size is becoming increasingly important because it enables economies of scale in technology, logistics, and marketing. In this context, it was a logical step for Uber to recently increase its stake in the German company further. The share has nearly doubled in the last four weeks.

    Including securities instruments, Uber has secured access to voting rights of nearly 37%. At the same time, another major shareholder, Aspex Fund, reduced its stake from 14.55% to 7.56%. By acquiring Delivery Hero, Uber could significantly strengthen its market position and gain access to numerous markets.

    Commerzbank: Independence Is Better

    Commerzbank is currently at the center of one of Europe's biggest takeover battles. Italy's UniCredit has now increased its stake to more than 34% of the share capital and holds additional derivative positions.

    But the financial institution is resisting a takeover and has advised its shareholders not to accept the offer, as it does not include an appropriate takeover premium and does not reflect the company's actual value.

    To make its independence more attractive, the bank has raised its profitability targets and announced job cuts. The Italians' courtship has benefited the stock price in the past. The figures also show that the major bank's business is running smoothly. It remains exciting.


    Investments by strategic investors and takeover speculation clearly create additional value for shareholders. This can be seen in examples as diverse as Delivery Hero and Commerzbank. **BioNxt Solutions could also emerge as a potential takeover candidate in the future. The Canadian company is developing a range of innovative solutions and proprietary platforms. Its portfolio is expanding, and commercialization has already begun in certain areas. If BioNxt Solutions' approach succeeds in establishing itself as an alternative to weight-loss injections, it could open up a multi-billion-dollar market opportunity. At present, however, the company's share price does not appear to reflect this potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 20th, 2026 | 05:55 CET

    Two sides of the same coin: America's legacy liabilities are Zefiro's opportunity! Analysts are extremely bullish!

    • Methane
    • Oil and gas
    • Orphan Wells
    • Climate change
    • Investments

    Created and published on behalf of Zefiro Methane Corp.

    Over a period of 20 years, methane has around 80 times the global warming impact of the same mass of CO₂. Preventing methane emissions can therefore deliver results relatively quickly. This explains the political focus on leaks and the plugging of abandoned and orphaned wells. Under the Infrastructure Investment and Jobs Act (IIJA), the US government has earmarked around USD 4.7 billion to plug and remediate orphan wells. "Orphan" means that no responsible operator can be held accountable. One lesser-known beneficiary of this situation is Zefiro Methane. The company is an established hidden champion in the US and is steadily expanding its business both organically and through acquisitions. Having recently secured fresh capital, the company could soon be stepping up its operations significantly. Analysts see substantial share price upside.

    Read

    Commented by Carsten Mainitz on November 20th, 2026 | 05:55 CET

    Gold Below USD 4,000! Central Bank Buying at Record Highs! What Matters Now for Kobo Resources, Barrick and Deutsche Börse!

    • Gold
    • Precious metals
    • Explorer
    • Gold producer
    • Xetra-Gold
    • Stock exchange
    • Investments
    • Real assets
    • Interest rates
    • Inflation
    • US dollar
    • Safe-haven currency

    Central banks are massively increasing their gold reserves, yet the price is falling to a 14-month low. The World Gold Council estimates net purchases in the third quarter at 321 tonnes. China's central bank bought 26 tonnes of gold in October alone, the largest monthly purchase in three years. But why is the price of the precious metal falling? The explanation lies in the bond market, among other factors. Signals from the US Federal Reserve make further interest rate rises more likely. The US dollar also strengthened. However, long-term investors should remain calm. Central bank purchases and its role as a safe-haven currency amid spiralling government debt are ultimately the most compelling arguments. Goldman Sachs sees a price target of USD 4,650 by the end of 2027. How should investors position themselves now - explorer, producer or product?

    Read